HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report)’s stock price rose 5.7% during mid-day trading on Wednesday . The stock traded as high as $2.59 and last traded at $2.59. Approximately 100 shares were traded during trading, a decline of 88% from the average daily volume of 837 shares. The stock had previously closed at $2.45.
Analyst Upgrades and Downgrades
Separately, Raymond James decreased their target price on HLS Therapeutics from $6.50 to $5.00 and set a “market perform” rating for the company in a research report on Monday, March 18th.
View Our Latest Analysis on HLTRF
HLS Therapeutics Stock Up 5.7 %
HLS Therapeutics Company Profile
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.
Featured Articles
- Five stocks we like better than HLS Therapeutics
- What is a Low P/E Ratio and What Does it Tell Investors?
- Constellation Brands Stock Q1 2025: Crushing Anheuser-Busch?
- Transportation Stocks Investing
- Qualcomm Stock Continues to Rise in the Face of Negative News
- How to Choose Top Rated Stocks
- Top 3 Summer Stocks with Solid Growth Opportunities
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
